Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
86 hedge funds and large institutions have $284M invested in Marinus Pharmaceuticals, Inc in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 14 closing their positions.
793% more call options, than puts
Call options by funds: $8.87M | Put options by funds: $994K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
72% more capital invested
Capital invested by funds: $166M → $284M (+$118M)
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
18% more funds holding
Funds holding: 73 → 86 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$8.38M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.53M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$7.41M |
| 4 |
Barclays
London,
United Kingdom
|
+$3.92M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
-$10M |
| 2 |
VA
VR Adviser
New York
|
-$7.05M |
| 3 |
AC
Antara Capital
New York
|
-$6.76M |
| 4 |
Walleye Capital
New York
|
-$5.08M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.27M |
MRNS Hedge Fund Activity: Q1 2023 in Review
86 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2023, worth a combined $284M — up 72% from $166M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new MRNS positions and 14 closed out — a net gain of 13 holders — while 31 added to existing stakes and 22 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $8.38M. The largest seller was Lion Point Capital, cutting an estimated $10M.
- 86 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2023, up from 73 in Q4 2022.
- Funds reported $284M of Marinus Pharmaceuticals, Inc stock for Q1 2023, up 72% quarter-over-quarter.
- 27 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2023 and 14 closed out, a net change of +13 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2023 was AIGH Capital Management, an estimated $8.38M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2023 was Lion Point Capital, an estimated $10M sold.
Based on aggregated 13F filings for Q1 2023.